Devaluation, by making imports more expensive, has posed a new challenge to the pharmaceutical industry which is significantly dependent on imports of raw materials and intermediates. The recently-announced liberal import policy can help the industry to face the challenge if it is continued for some years.
But the main task is the industry's, in cost reduction and import substitution. However not much progress is possible in import substitution without developing a basic organic chemicals complex.
